scPharmaceuticals (SCPH)
(Delayed Data from NSDQ)
$4.58 USD
+0.09 (2.00%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $4.59 +0.01 (0.22%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for scPharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 76 | 118 | 75 | 105 | 73 |
Receivables | 4 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 9 | 1 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 3 | 3 | 3 |
Total Current Assets | 93 | 123 | 78 | 108 | 76 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 94 | 124 | 79 | 109 | 77 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 1 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 10 | 2 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 5 | 4 | 5 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 13 | 7 | 15 | 9 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 39 | 37 | 7 | 17 | 19 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 8 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 57 | 52 | 23 | 27 | 26 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 319 | 299 | 246 | 244 | 181 |
Retained Earnings | -281 | -227 | -190 | -162 | -129 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 37 | 72 | 56 | 82 | 51 |
Total Liabilities & Shareholder's Equity | 94 | 124 | 79 | 109 | 77 |
Total Common Equity | 37 | 72 | 56 | 82 | 51 |
Shares Outstanding | 35.80 | 34.20 | 27.30 | 27.30 | 18.60 |
Book Value Per Share | 1.04 | 2.12 | 2.07 | 3.01 | 2.76 |
Fiscal Year End for scPharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 76 | 90 | 103 | 116 |
Receivables | NA | 4 | 4 | 2 | 3 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 9 | 7 | 6 | 4 |
Other Current Assets | NA | 4 | 3 | 3 | 4 |
Total Current Assets | NA | 93 | 104 | 114 | 127 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 94 | 106 | 114 | 127 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 3 | 1 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 7 | 5 | 6 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 13 | 11 | 7 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 39 | 38 | 38 | 37 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 6 | 6 | 7 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 57 | 57 | 51 | 52 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 319 | 317 | 315 | 314 |
Retained Earnings | NA | -281 | -268 | -252 | -238 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 37 | 49 | 63 | 76 |
Total Liabilities & Shareholder's Equity | NA | 94 | 106 | 114 | 127 |
Total Common Equity | 0 | 37 | 49 | 63 | 76 |
Shares Outstanding | 36.00 | 35.80 | 35.80 | 35.70 | 35.70 |
Book Value Per Share | 0.00 | 1.04 | 1.37 | 1.78 | 2.12 |